

# Immune Checkpoint Inhibitors in RCC

- Risk stratification using prognostic models play an important role in treatment decision making for patients with metastatic renal cell carcinoma (mRCC).
- Immuno-oncology (IO) agents, either alone or in combination with targeted therapies, have become firmly established treatment options for patients of all risk groups with mRCC.
- Early recognition of immune related adverse events (AEs) is critical as discontinuation of treatment and systemic corticosteroids can prevent life-threatening consequences.
- There are multiple clinical trials using IO agents in the peri-operative setting for patients with localized high risk RCC and in patients with non-clear cell mRCC.
- Referral and recruitment of patients for clinical trials is paramount for improving survival in patients with mRCC.



American  
Urological  
Association

Education & Research, Inc.